Physician profile
Deborah J Levine
NPI 1831206804
$166,148.01
in general payments reported to CMS, 2019-2025
17 companies · $3,992 in 2025
The $3,992 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69K · 2020: $28K · 2021: $19K · 2022: $14K · 2023: $11K · 2024: $22K · 2025: $3,992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $15K · Consulting Fee: $9,669 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,325 · Honoraria: $3,500 · Food and Beverage: $1,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $14,961.19 |
| Consulting Fee | $9,668.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,325.00 |
| Honoraria | $3,500.00 |
| Food and Beverage | $1,386.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $78,479.22 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $28,144.67 | 2019-2022 | |
| Zambon USA Ltd. | $26,333.23 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $13,570.85 | 2023-2024 | Winrevair |
| United Therapeutics Corporation | $8,824.62 | 2019-2025 | Tyvaso, Steen Solution |
| One Lambda, INC. | $3,161.67 | 2019-2021 | |
| Kamada Ltd. | $2,705.57 | 2023-2025 | |
| Glaxosmithkline, LLC. | $2,000.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $1,275.93 | 2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $601.63 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $491.67 | 2021 | |
| Paragonix Technologies, INC. | $282.35 | 2024 | Lungguard, Baroguard, Sherpapak |
| Alexion Pharmaceuticals, INC. | $150.00 | 2019 | |
| Therakos LLC | $92.22 | 2025 | |
| La Jolla Pharmaceutical Company | $34.38 | 2025 | Giapreza |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.